Myeloma

The Myeloma Program is a highly interdisciplinary group of investigators dedicated to reducing the incidence and subsequent mortality of Myeloma. The program fosters interdisciplinary research in basic science, genetics, clinical medicine, cancer prevention, and epidemiology at Fred Hutch, the faculty at the University of Washington, and the clinical community to improve lymphoma prevention, detection, diagnosis and treatment. 

Program Strengths

Forty years ago, researchers at Fred Hutch developed bone marrow transplantation, which continues to be one of the most effective options for patients with Myeloma. Dr. E. Donnall Thomas and his team proved it is possible to replace cancerous cells and stem cells with donated healthy cells that engraft within a patient’s bone marrow. The discovery has created an effective treatment option for Myeloma and other blood cancers, and earned Thomas the 1990 Nobel Prize in physiology or medicine.

Personalized Care

Our team is a global leader in myeloma and performs more transplants than any other center. Our clinicians see a high volume of myeloma patients, and as a result are experts in the management of disease. Our clinicians know the limitations of current treatment options and are able to maximize health outcomes while managing treatment

multiple myeloma graphic

Dr. Damian Green
STTR Myeloma Deputy Director

Dr. Green is a translational oncologist and stem cell transplant specialist who cares for patients with blood disorders. His clinical expertise is in multiple myeloma, lymphoma, amyloidosis, stem cell transplantation, and radioimmunotherapy. Dr. Green’s laboratory and his clinical research program are focused on developing new immunotherapeutic approaches to treat and ultimately eradicate multiple myeloma and lymphoma.

Learn more at the Green Group